Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03409419 · ClinicalTrials.gov registry record
PET Imaging of the Immune System Using Analog Probes
A clinical trial, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- 4
- Enrollment target
NCT03409419: Completed study, sponsored by Jonsson Comprehensive Cancer Center.
NCT03409419 is a clinical trial that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03409419 has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
The goal of this proposal is to assess the biodistribution of 18F-Clofarabine, a new tracer developed for use in PET/CT scans. The investigator's hypothesis is this tracer will allow for imaging immune activation in patients with melanoma before and after treatment with immunotherapy. A maximum of 10 subjects are intended to be included in this study. Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans, with each visit taking up to 4 hours. The first visit will be prior to the first cycle of immunotherapy treatment, and the second scan will take place 2-4 weeks after the immunotherapy treatment has started. Prior to the PET scan an IV line will be placed. Blood pressure, heart rate, blood oxygen and ECG will be obtained. Then the 18F-Clofarabine will be injected and the PET/CT scan acquisition started. After a maximum of 120 min of scanning, subjects will undergo again blood pressure, heart rate, blood oxygen and ECG.
Primary Outcome
The biodistribution of 18F-Clofarabine in melanoma patients
Interventions
- DRUG [18F] CFA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-04-10 |
| Est. Completion | 2020-11-10 |
What the finished NCT03409419 record still lists
NCT03409419 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which [18F] CFA is the first listed.
NCT03409419 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03409419 about?
NCT03409419 is a clinical study titled "PET Imaging of the Immune System Using Analog Probes". The goal of this proposal is to assess the biodistribution of 18F-Clofarabine, a new tracer developed for use in PET/CT scans. The investigator's hypothesis is this tracer will allow for imaging immune activation in patients with melanoma before and after treatment with immunotherapy. A maximum of ...
What is the current status of trial NCT03409419?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2018-04-10. Estimated completion is 2020-11-10.
What interventions are being tested in trial NCT03409419?
The interventions under investigation include: [18F] CFA (DRUG).
Who is sponsoring clinical trial NCT03409419?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI